Novartis Newswire

Novartis Newswire

Comprehensive Real-Time News Feed for Novartis.

Results 1 - 20 of 882 in Novartis

  1. The rise of the "unbranded" pharmaceutical adRead the original story w/Photo

    16 hrs ago | CBS News

    ... about a potentially life-threatening issue, the ads point consumers to a website where they can learn more. Take a Novartis ( NVS ) ad that highlighted the issue of heart failure. The TV spot showed a man reading a newspaper from his armchair, while ...

    Comment?

  2. Here's What's Important With The Novartis AG (ADR) (NVS) MS DataRead the original story w/Photo

    17 hrs ago | Insider Monkey

    ... users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member. Novartis AG (ADR) (NYSE: NVS ) just put out data from its multiple sclerosis (MS) trial, and it looks as if the company is winning the ...

    Comment?

  3. CTI Bio's late-stage study of lead product candidate pacritinib shows ...Read the original story w/Photo

    23 hrs ago | Seeking Alpha

    Top-line data from CTI BioPharma's Phase 3 clinical trial, PERSIST-2, assessing lead product candidate pacritinib against physician-specified best available therapy , including Novartis' Jakavi , in patients with advanced myelofibrosis showed statistically valid results in one of two co-primary endpoints. The results were generated from 221 patients who reached the primary analysis time point of Week 24 at the time the clinical hold was imposed by the FDA.

    Comment?

  4. Hills Bank & Trust Co. Cuts Stake in Novartis AGRead the original story w/Photo

    Sunday | Daily Political

    Hills Bank & Trust Co. decreased its position in Novartis AG by 6.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission .

    Comment?

  5. Novartis AG (NVS) Stake Raised by Trust Co. of VermontRead the original story w/Photo

    Sunday | Daily Political

    Trust Co. of Vermont increased its position in shares of Novartis AG by 4.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission.

    Comment?

  6. Momenta Has Momentum After Recent Patent DecisionRead the original story w/Photo

    Sunday | Seeking Alpha

    ... and creates a revenue path well in advance of when it was expected. Momenta is working on developing Copaxone with Novartis' (NYSE: NVS ) generic division Sandoz. The companies have already launched a once-daily version of Copaxone, which was ...

    Comment?

  7. Novartis AG (NVS) Sees Large Volume IncreaseRead the original story w/Photo

    Saturday Aug 27 | Daily Political

    Novartis AG saw unusually-strong trading volume on Thursday . Approximately 1,075,652 shares traded hands during trading, a decline of 3% from the previous session's volume of 1,104,592 shares.The stock last traded at $80.04 and had previously closed at $80.30.

    Comment?

  8. Can Novartis Tide Over the Alcon Crisis?Read the original story w/Photo

    Friday Aug 26 | GuruFocus.com

    With Novartis falling off the patent cliff with its blockbuster cancer drug Gleevec which lost steam due to the impact of generics Novartis is down nearly 11% since the start of the year; at 3.87 times price to sale the company looks like an attractive investment. For the sake of comparison, Pfizer , which saw a similar revenue decline this year, has been on an acquisition spree to bolster its top line, and the company is now trading at 4.08 times sales at the writing of this article.

    Comment?

  9. AbbVie Inc (ABBV) Expected To Launch Zinbryta In The US This MonthRead the original story w/Photo

    Friday Aug 26 | Insider Monkey

    ... bryta is expected to become a key option for MS patients in the US. It will compete with other MS players including Novartis AG (ADR) (NYSE: NVS ) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA ).

    Comment?

  10. Novartis AG (NVS) Announces Positive Phase III Results For MS DrugRead the original story w/Photo

    Friday Aug 26 | Insider Monkey

    ... users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member. Novartis AG (NYSE: NVS ) has announced that the Phase III EXPAND study, which is evaluating the efficacy and safety of oral, once ...

    Comment?

  11. Novartis AG (NVS) is Hemenway Trust Co LLC's 9th Largest PositionRead the original story w/Photo

    Friday Aug 26 | Daily Political

    Hemenway Trust Co LLC increased its stake in Novartis AG by 4.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission . The institutional investor owned 131,826 shares of the company's stock after buying an additional 5,830 shares during the period.

    Comment?

  12. 7 Healthcare Dividend Stocks for Quality and SecurityRead the original story w/Photo

    Friday Aug 26 | Kiplinger Online

    ... of products has been revamped in recent years. The pharma giant recently conducted a multi-step deal with rival Novartis AG ( NVS ) for Novartis' profitable vaccine business, as well as its hefty consumer products portfolio, in exchange for Glaxo's ...

    Comment?

  13. Siponimod Rides To Novartis' RescueRead the original story w/Photo

    Thursday Aug 25 | Seeking Alpha

    Novartis' Gilenya quietly seized third place among the world's best-selling multiple sclerosis therapies last year, but the fun is about to end as it faces US patent expiry in 2019. As of today, however, the Swiss group can boast a new pillar for its Gilenya follow-on plan: siponimod, a similarly acting project, has posted an unexpected phase III success.

    Comment?

  14. Novartis AG (NVS) Earns Hold Rating from ArgusRead the original story w/Photo

    Thursday Aug 25 | AmericanBankingNews.com

    Several hedge funds recently made changes to their positions in NVS. Franklin Resources Inc. raised its stake in shares of Novartis AG by 22.4% in the first quarter.

    Comment?

  15. Novartis' BAF312 successful in late-stage multiple sclerosis studyRead the original story w/Photo

    Thursday Aug 25 | Seeking Alpha

    Novartis' Phase 3 study, EXPAND, assessing BAF312 for the treatment of secondary progressive multiple sclerosis met its primary endpoint of a reduction in the risk of disability progression versus placebo. Top-line data will be presented on September 17 at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis in London.

    Comment?

  16. InnerWorkings Worth A Look?Read the original story w/Photo

    Wednesday Aug 24 | Seeking Alpha

    ... Callaway (NYSE: ELY ), L'Oreal ( OTCPK:LRLCY ), Unilever (NYSE: UL ), Party City (NYSE: PRTY ), ADT (NYSE: ADT ), Novartis (NYSE: NVS ), AstraZeneca (NYSE: AZN ), Energizer (NYSE: ENR ) and Pizza Hut. To familiarize you more with INWK here are some ...

    Comment?

  17. Merck Offers Value and Steady Dividend GrowthRead the original story

    Wednesday Aug 24 | GuruFocus.com

    ... largest pharmaceutical companies in the world by market capitalization, only behind Johnson & Johnson ( NYSE:JNJ ), Novartis ( NYSE:NVS ), and Pfizer ( PFIZER ). Compared to these competitors, Merck had sales of over $39 billion in 2015 versus $70.1 ...

    Comment?

  18. Blair William & Co. IL Cuts Stake in Novartis AGRead the original story w/Photo

    Wednesday Aug 24 | Daily Political

    Blair William & Co. IL cut its position in Novartis AG by 8.3% during the second quarter, Holdings Channel reports.

    Comment?

  19. Cyon Therapeutics Inc. Acquires World-Wide Rights To An Anti-PCSK9...Read the original story

    Monday Aug 22 | BioSpace

    /PRNewswire/ - Cyon Therapeutics Inc.(Cyon) today announced that it has entered into a license agreement with Novartis AG (NYSE:NVS) for their anti-PCSK9 antibody, LGT-209. The licensing deal brings with it worldwide rights for use in SIRS (systemic ...

    Comment?

  20. ARIAD Pharmaceuticals Could Be Benefiting From Prescriber EducationRead the original story w/Photo

    Tuesday Aug 23 | Seeking Alpha

    ... BCR-ABL1 oncogene that in turn produces the protein BCR-ABL1 kinase, a target of first-generation TKI Gleevec from Novartis (NYSE: NVS ) and second-generation (G2) TKIs Sprycel from Bristol-Myers Squibb Company (NYSE: BMY ), Novartis' Tasigna, and ...

    Comment?